Johnson & Johnson recalls schizophrenia drug after discovering mold

(Reuters) – Johnson & Johnson is voluntarily recalling one lot of schizophrenia drug Risperdal Consta after discovering mold during a routine testing process, a company spokeswoman said, the latest in a string of recalls over the past two years. Risperdal Consta is manufactured by Janssen Pharmaceuticals, a unit of Johnson & Johnson. The company is recalling the drug from wholesalers, distributors, pharmacies and healthcare providers. The medicine is a long-acting form of J&J’s Risperdal anti-psychotic medication, and is used to treat bipolar disorder and schizophrenia. …